Cargando…

Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder

PURPOSE: Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Chappuy, Mathieu, Meroueh, Fadi, Trojak, Benoit, Bachellier, Jérôme, Bendimerad, Patrick, Kosim, Margaux, Hjelmström, Peter, Nubukpo, Philippe, Brousse, Georges, Rolland, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214559/
https://www.ncbi.nlm.nih.gov/pubmed/34163143
http://dx.doi.org/10.2147/PPA.S311674
_version_ 1783710089520087040
author Chappuy, Mathieu
Meroueh, Fadi
Trojak, Benoit
Bachellier, Jérôme
Bendimerad, Patrick
Kosim, Margaux
Hjelmström, Peter
Nubukpo, Philippe
Brousse, Georges
Rolland, Benjamin
author_facet Chappuy, Mathieu
Meroueh, Fadi
Trojak, Benoit
Bachellier, Jérôme
Bendimerad, Patrick
Kosim, Margaux
Hjelmström, Peter
Nubukpo, Philippe
Brousse, Georges
Rolland, Benjamin
author_sort Chappuy, Mathieu
collection PubMed
description PURPOSE: Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous findings have shown that incarcerated subjects were not less interested in XR-BUP than non-incarcerated subjects. However, no study has ever investigated whether the factors of interest in XR-BUP were similar in incarcerated and non-incarcerated populations. PATIENTS AND METHODS: We carried out post-hoc analyses using data from the “AMBRE” survey, which was conducted among 366 individuals with OUD, that were recruited in 68 French addiction settings, including six prison medical centers. The reasons for interest in XR-BUP were compared between incarcerated and non-incarcerated interviewees, using logistic regressions models, which provided raw and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI). Adjustment variables were gender, age category, level of education, and type of current medication for OUD, respectively. RESULTS: Data from 317 participants (ie, 221 non-incarcerated, and 96 incarcerated individuals) were included in the analyses. Adjusted comparisons found that “no longer taking a daily treatment” (aOR= 2.91; 95% CI= 1.21–6.98) and “having a more discreet medication” (aOR= 1.76; 95% CI= 1.01–3.10) were reasons that appealed more to incarcerated participants than to non-incarcerated ones. On the other hand, the potential reduction of withdrawal symptoms (aOR= 0.54; 95% CI= 0.29–0.99) or the risk of misuse (aOR= 0.56; 95% CI= 0.34–0.94) associated with XR-BUP treatment were considered more important by non-incarcerated individuals than by incarcerated ones. CONCLUSION: Incarcerated interviewees were interested in XR-BUP for different reasons than those outside prison. In particular, incarcerated patients were more interested in practicability and discretion features, and less in improving recovery or reducing misuse than non-incarcerated patients.
format Online
Article
Text
id pubmed-8214559
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82145592021-06-22 Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder Chappuy, Mathieu Meroueh, Fadi Trojak, Benoit Bachellier, Jérôme Bendimerad, Patrick Kosim, Margaux Hjelmström, Peter Nubukpo, Philippe Brousse, Georges Rolland, Benjamin Patient Prefer Adherence Original Research PURPOSE: Extended-release buprenorphine (XR-BUP) covers a range of formulations of buprenorphine-based treatments for opioid use disorder (OUD) that release the medication over a period of one week, one month, or six months. OUD is particularly prevalent among incarcerated populations, and previous findings have shown that incarcerated subjects were not less interested in XR-BUP than non-incarcerated subjects. However, no study has ever investigated whether the factors of interest in XR-BUP were similar in incarcerated and non-incarcerated populations. PATIENTS AND METHODS: We carried out post-hoc analyses using data from the “AMBRE” survey, which was conducted among 366 individuals with OUD, that were recruited in 68 French addiction settings, including six prison medical centers. The reasons for interest in XR-BUP were compared between incarcerated and non-incarcerated interviewees, using logistic regressions models, which provided raw and adjusted odds ratios (aORs) and 95% confidence intervals (95% CI). Adjustment variables were gender, age category, level of education, and type of current medication for OUD, respectively. RESULTS: Data from 317 participants (ie, 221 non-incarcerated, and 96 incarcerated individuals) were included in the analyses. Adjusted comparisons found that “no longer taking a daily treatment” (aOR= 2.91; 95% CI= 1.21–6.98) and “having a more discreet medication” (aOR= 1.76; 95% CI= 1.01–3.10) were reasons that appealed more to incarcerated participants than to non-incarcerated ones. On the other hand, the potential reduction of withdrawal symptoms (aOR= 0.54; 95% CI= 0.29–0.99) or the risk of misuse (aOR= 0.56; 95% CI= 0.34–0.94) associated with XR-BUP treatment were considered more important by non-incarcerated individuals than by incarcerated ones. CONCLUSION: Incarcerated interviewees were interested in XR-BUP for different reasons than those outside prison. In particular, incarcerated patients were more interested in practicability and discretion features, and less in improving recovery or reducing misuse than non-incarcerated patients. Dove 2021-06-14 /pmc/articles/PMC8214559/ /pubmed/34163143 http://dx.doi.org/10.2147/PPA.S311674 Text en © 2021 Chappuy et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chappuy, Mathieu
Meroueh, Fadi
Trojak, Benoit
Bachellier, Jérôme
Bendimerad, Patrick
Kosim, Margaux
Hjelmström, Peter
Nubukpo, Philippe
Brousse, Georges
Rolland, Benjamin
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
title Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
title_full Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
title_fullStr Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
title_full_unstemmed Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
title_short Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder
title_sort factors of interest in extended-release buprenorphine: comparisons between incarcerated and non-incarcerated patients with opioid use disorder
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214559/
https://www.ncbi.nlm.nih.gov/pubmed/34163143
http://dx.doi.org/10.2147/PPA.S311674
work_keys_str_mv AT chappuymathieu factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT merouehfadi factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT trojakbenoit factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT bachellierjerome factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT bendimeradpatrick factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT kosimmargaux factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT hjelmstrompeter factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT nubukpophilippe factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT broussegeorges factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder
AT rollandbenjamin factorsofinterestinextendedreleasebuprenorphinecomparisonsbetweenincarceratedandnonincarceratedpatientswithopioidusedisorder